Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > DRI Capital Inc. Acquires Royalties from Nanogen Inc. for US$10 Million

Abstract:
DRI Capital Inc. (DRI) and Nanogen, Inc. (Nasdaq:NGEN) announced today that they have entered into an agreement for DRI to acquire, for US$10 million, all future royalties generated by Applied Biosystems (ABI) under a license ABI has taken from Nanogen for MGB™ (minor groove binder) technology.

DRI Capital Inc. Acquires Royalties from Nanogen Inc. for US$10 Million

TORONTO, Canada and SAN DIEGO, CA | Posted on March 31st, 2008

"This transaction extends DRI's interests in royalties related to molecular biology research tools," said Joshua Salisbury, Managing Director at DRI. "This agreement is another example of the tailored and innovative sources of capital DRI offers and we are pleased that we were able to work with Nanogen again."

"Monetizing this royalty stream provides us with a non-dilutive means of raising capital to fund our operations as we work towards achieving cash flow breakeven in late 2008," said Howard C. Birndorf, Nanogen chairman and chief executive officer.

The royalty payments included in the agreement are related to Nanogen's patented MGB™ technology that has been licensed to ABI for use in ABI's TaqMan® products (TaqMan® is a registered trademark of Roche Molecular Systems, Inc.). ABI's TaqMan® assays library using Nanogen's MGB™ is the leading life science research product library for PCR applications. Nanogen's MGB™ technology provides many advantages in the design of oligonucleotide probes, and has become a sought after component for many companies working in the molecular detection and diagnostic marketplace. Nanogen has an active partnering and licensing program and has more than 40 patents related to nucleic acid detection.

About DRI Capital

DRI Capital is a privately held investment management company, focused on the healthcare industry, with over US$1 billion under management. DRI Capital currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

The Royalty Monetization Fund acquires existing royalty streams at competitive rates from companies, institutions and inventors. DRI Capital is a leader in monetizing royalties, having acquired over US$850 million in royalty-based cash flows on commercialized products. In 2007 alone, DRI Capital has deployed about US$450 million with royalty acquisitions on products such as Enbrel, Flumist, Preotact and PEG-INTRON.

The Structured Finance Fund, launched in January 2008 with approximately US$300 million, is a hybrid debt and equity fund which invests in commercial stage healthcare products through investments in synthetic royalties, debt, and structured debt/equity instruments. The fund focuses on commercial stage pharmaceuticals and medical devices and is not limited to a therapeutic category or market segment. The financing that the Structured Finance Fund provides, which is primarily non-dilutive, allows for companies to finance in-licensing and new product acquisitions, sales force expansions, or fund additional capital needs.

www.dricapital.com

####

About Nanogen, Inc.
(Nasdaq: NGEN - News) has a strong product and proprietary technology base of diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) markets—molecular diagnostics and rapid point-of-care testing. The company provides their innovative, high-quality diagnostic products to clinicians and physicians worldwide, making it easier to predict and diagnose diseases, ultimately improving patient care. Products include molecular diagnostic kits and reagents, and kits for rapid, point-of-care testing. Nanogen has pioneered research in areas involving biomedical markers, molecular biology and nanotechnology to bring better results to diagnostics and healthcare.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from these forward-looking statements due to a number of factors and, consequently, you should not rely on such forward looking statement as prediction of future event. These factors include, but are not limited to, the Company’s ability to achieve cash flow breakeven, ability to obtain financing, its ability to comply with the terms of its outstanding indebtedness, ability to remain listed on the NASDAQ Global Market, whether patents owned or licensed by the Company will be developed into products, whether the patents owned by Company offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption “Risk Factors” in the Company’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

For more information, please click here

Contacts:
Nanogen, Inc.
Nick Venuto, CFO
858-410-4600

or
DRI Capital
Joshua Salisbury, Managing Director, Healthcare Funds
416-324-5712

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Announcements

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Patents/IP/Tech Transfer/Licensing

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Making Batteries From Waste Glass Bottles: UCR researchers are turning glass bottles into high performance lithium-ion batteries for electric vehicles and personal electronics April 19th, 2017

'Neuron-reading' nanowires could accelerate development of drugs for neurological diseases April 12th, 2017

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Alliances/Trade associations/Partnerships/Distributorships

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

BASF and Landa partner to create revolutionary pigments for automotive coatings: The alliance combines BASF innovations with Landa nano-pigment technology April 5th, 2017

Leti Announces EU/South Korean Project for World’s First 5G-system Prototype: Coinciding with the 2018 Winter Games in PyeongChang, Korea, Prototype Will Be First Time State-of-the-art Terrestrial Wireless Communication Is Seamlessly Combined with Disruptive Satellite Communicati April 4th, 2017

ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project